Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00044096 · ClinicalTrials.gov registry record

Psychopharmacology of Fear-Potentiated Startle in Humans

A clinical trial, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
225
Enrollment target

NCT00044096 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 225 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00044096 has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
225 participants
Enrollment target

Study Summary

The purpose of this study is to understand the effects of the drug alprazolam (Xanax ) on anxiety. To understand the effect of anxiety-relieving drugs on fear and anxiety, researchers often have participants anticipate unpleasant stimuli. Anticipating unpleasant stimuli increases or potentiates a simple reflex called the startle reflex. The so-called fear-potentiated startle reflex (FPS) effect may be blocked or reduced by anxiety-relieving drugs. Evidence suggests that the FPS can be mediated by two mechanisms that regulate the phasic- and sustained enhancement of startle. This study will elicit phasic and sustained FPS in participants by having them anticipate moderately painful stimuli that are administered predictably and unpredictably. The main goal of this study is to assess the affect of alprazolam on the phasic and sustained enhancement of startle. This study comprises two pilot experiments and a main study. Participants in the study will be screened with a psychiatric history, physical examination, electrocardiogram (EKG), and blood and urine tests. Participants will four testing sessions separated by 5 to 10 days. At each session, participants will be given one of two doses of alprazolam, diphenhydramine, or placebo (an inactive pill). Questionnaires and other tests will be performed.

Trial Details

FieldValue
Enrollment Target 225 participants
Start Date 2002-08-15
Est. Completion 2013-09-17

What the Registry Record Tells You About NCT00044096

The ClinicalTrials.gov registry entry for NCT00044096 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00044096 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00044096 about?

NCT00044096 is a clinical study titled "Psychopharmacology of Fear-Potentiated Startle in Humans". The purpose of this study is to understand the effects of the drug alprazolam (Xanax ) on anxiety. To understand the effect of anxiety-relieving drugs on fear and anxiety, researchers often have participants anticipate unpleasant stimuli. Anticipating unpleasant stimuli increases or potentiates a s...

What is the current status of trial NCT00044096?

This trial is currently completed. The enrollment target is 225 participants. The study started on 2002-08-15. Estimated completion is 2013-09-17.

Who is sponsoring clinical trial NCT00044096?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.